SCHEMBL14405083

SCHEMBL14405083

CC1CN(S(=O)(=O)Cc2ccc(N)c(Br)c2)C[C@H](C)N1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.39
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
AKR1C3 P42330 1/20 0.34
NAMPT P43490 2/20 0.34
GHSR Q92847 1/20 0.34
SIGMAR1 Q99720 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPC1 O15118 1/20 0.32
CTSD P07339 1/20 0.32
BACE1 P56817 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650117 1.00 CSF1R (0.39) CSF1RCA12CA1CA2CA4
SCHEMBL5650123 1.00 CSF1R (0.39) CSF1RCA12CA1CA2CA4
SCHEMBL14404923 0.81 L3MBTL1 (0.40) CSF1RAKR1C3NAMPTSIGMAR1L3MBTL1
SCHEMBL5650093 0.81 L3MBTL1 (0.40) CSF1RAKR1C3NAMPTSIGMAR1L3MBTL1
SCHEMBL5650089 0.81 L3MBTL1 (0.40) CSF1RAKR1C3NAMPTSIGMAR1L3MBTL1
SCHEMBL4333962 0.78 CSF1R (0.56) CSF1RAKR1C3GHSR
SCHEMBL14405148 0.78 CSF1R (0.56) CSF1RAKR1C3GHSR
SCHEMBL5648977 0.78 CSF1R (0.56) CSF1RAKR1C3GHSR
SCHEMBL4180920 0.75 LMNA (0.43) CA12CA1CA2CA4CA6
SCHEMBL5650248 0.74 HTT (0.46) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249649-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249649-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885CA12 1317/4885CA1 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.